Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of malignant solid tumor
• •* Metastatic or inoperable disease
• •No known curative or survival-prolonging palliative therapy exists OR failed these prior therapies
• •No leukemia
• •No primary CNS tumor
• •No third-space fluid collection (i.e., pleural effusion, ascites)
• •* Clinically insignificant small pleural or peritoneal effusions identified by CT scan, MRI, or other diagnostic test allowed
• •No active\* brain metastases, including the following:
• •* Evidence of cerebral edema by CT scan or MRI
• •* Progression since prior imaging study
• •* Requirement for steroids
• •* Clinical symptoms of/from brain metastases NOTE: \*Treated and/or stable brain metastasis allowed provided patient is asymptomatic
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •At least 2 months
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •RBC folate ≥ lower limit of normal
• •Hepatic
• •Bilirubin normal
• •SGOT and SGPT ≤ 2.5 times upper limit of normal
• •Renal
• •Creatinine clearance ≥ 50 mL/min
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No other uncontrolled serious medical or psychiatric illness
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No prior bone marrow transplantation
• •Chemotherapy
• •More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• •Endocrine therapy
• •See Disease Characteristics
• •Radiotherapy
• •More than 3 weeks since prior radiotherapy
• •No concurrent radiotherapy
• •Surgery
• •At least 3 weeks since prior surgery
• •Other
• •Recovered from prior therapy
• •More than 3 weeks since prior antifolate therapy